Joshi Laxminarayan - Canntab Therapeutics Chief Officer
| CTABF Stock | USD 0.0001 0.00 0.00% |
Insider
Joshi Laxminarayan is Chief Officer of Canntab Therapeutics Limited
| Phone | 289 301 3812 |
| Web | https://canntab.ca |
Canntab Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.8211) % which means that it has lost $0.8211 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (6.0186) %, meaning that it generated substantial loss on money invested by shareholders. Canntab Therapeutics' management efficiency ratios could be used to measure how well Canntab Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| JD BA | HLS Therapeutics | 42 | |
| Francois Lafortune | Crescita Therapeutics | N/A | |
| Caitlin Johnston | Avicanna | N/A | |
| Tim MBA | HLS Therapeutics | 51 | |
| Patricia Colvin | Bionoid Pharma | N/A | |
| Mba BEcon | Avicanna | N/A | |
| Frantz Devedec | Avicanna | N/A | |
| Dominic KingSmith | Crescita Therapeutics | N/A | |
| Roland Alvarez | Avicanna | N/A | |
| Ivana Maric | Avicanna | N/A | |
| Sanjiv Sharma | HLS Therapeutics | 67 | |
| David Spence | HLS Therapeutics | 55 | |
| Gilbert Godin | HLS Therapeutics | 64 | |
| Carlos Muete | Avicanna | N/A | |
| BA LLB | HLS Therapeutics | 65 | |
Management Performance
| Return On Equity | -6.02 | |||
| Return On Asset | -0.82 |
Canntab Therapeutics Leadership Team
Elected by the shareholders, the Canntab Therapeutics' board of directors comprises two types of representatives: Canntab Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Canntab. The board's role is to monitor Canntab Therapeutics' management team and ensure that shareholders' interests are well served. Canntab Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Canntab Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| LLB BA, S Director | ||
| Eric Malinski, Director Marketing | ||
| Richard Goldstein, CoFounder, CEO | ||
| Joshi Laxminarayan, Chief Officer |
Canntab Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Canntab Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.02 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (26.95) % | |||
| Current Valuation | 1.73 M | |||
| Shares Outstanding | 38.91 M | |||
| Shares Owned By Insiders | 15.08 % | |||
| Price To Book | 4.74 X | |||
| Price To Sales | 1.83 X | |||
| Revenue | 293.36 K | |||
| Gross Profit | (939.01 K) |
Currently Active Assets on Macroaxis
Other Information on Investing in Canntab Pink Sheet
Canntab Therapeutics financial ratios help investors to determine whether Canntab Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canntab with respect to the benefits of owning Canntab Therapeutics security.